localized reaction to tirzepatide Injection Site Treatment: Evidence-Based Management Guide Bumps and humps in the
Description
Early pregnancy exposure carries different theoretical risk than exposure during organ development phases (8-12 weeks)
Retatrutide In the first phase 3 trial (TRIUMPH-4), participants lost an average of 28.7% of their body weight at 68 weeks on the highest dose (12mg), with the 9mg dose showing 26.4% weight loss
Some providers may request additional information or lab work before prescribing
Please Note: GLP-1 agonist medications are only available for patients aged 21 years and above
